Trevi Therapeutics Files 8-K Report
Ticker: TRVI · Form: 8-K · Filed: Dec 12, 2024 · CIK: 1563880
Sentiment: neutral
Topics: disclosure, regulatory-filing
Related Tickers: TRVI
TL;DR
Trevi Therapeutics dropped an 8-K, but the details are still under wraps.
AI Summary
On December 12, 2024, Trevi Therapeutics, Inc. filed an 8-K report. The filing indicates that the company is providing information under "Other Events." No specific details regarding new events, agreements, or financial transactions are detailed in the provided excerpt.
Why It Matters
This 8-K filing signals that Trevi Therapeutics is disclosing material information to the public, which could impact investor understanding of the company's current status.
Risk Assessment
Risk Level: low — The filing is a standard disclosure and does not contain information about significant risks or negative events.
Key Players & Entities
- Trevi Therapeutics, Inc. (company) — Registrant
- December 12, 2024 (date) — Date of report
- Delaware (jurisdiction) — State of Incorporation
- 001-38886 (filing_id) — Commission File Number
- 45-0834299 (tax_id) — IRS Employer Identification No.
- 195 Church Street, 16th Floor New Haven, Connecticut 06510 (address) — Principal Executive Offices
- (203) 304-2499 (phone_number) — Registrant's telephone number
FAQ
What specific event triggered this 8-K filing for Trevi Therapeutics?
The filing indicates the report is for 'Other Events,' but the provided text does not specify the exact event.
When was this 8-K report filed with the SEC?
The report was filed on December 12, 2024.
What is Trevi Therapeutics' state of incorporation?
Trevi Therapeutics, Inc. is incorporated in Delaware.
What is the principal executive office address for Trevi Therapeutics?
The principal executive offices are located at 195 Church Street, 16th Floor, New Haven, Connecticut 06510.
Does this filing provide any financial updates or material agreements?
The provided excerpt of the 8-K filing does not detail any specific financial updates or material agreements; it only states the filing is for 'Other Events'.
Filing Stats: 824 words · 3 min read · ~3 pages · Grade level 15.1 · Accepted 2024-12-12 08:00:08
Key Financial Figures
- $0.001 — e on which registered Common stock, $0.001 par value per share TRVI The Nasdaq
Filing Documents
- trvi-20241212.htm (8-K) — 47KB
- 0000950170-24-135602.txt ( ) — 166KB
- trvi-20241212.xsd (EX-101.SCH) — 28KB
- trvi-20241212_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events On December 12, 2024, Trevi Therapeutics, Inc., a Delaware corporation (the "Company"), announced the positive outcome from the planned sample size re-estimation (the "SSRE") for the ongoing Phase 2b CORAL trial in idiopathic pulmonary fibrosis patients with chronic cough, which requires no change to the current sample size for the trial (N=160). The trial has reached 75% of the targeted enrollment, and topline results from the full trial continue to be expected in the first half of 2025. The SSRE analysis was conducted on the highest dose (108mg twice daily) in the trial after 50% of the initial targeted trial enrollment, or 80 patients, completed the six weeks of treatment. Based on the SSRE analysis, it was recommended that the CORAL trial should continue as planned to maintain the pre-specified conditional power of 80% or greater. The other two potential pre-specified outcomes of the SSRE analysis were an increase in the sample size or futility.
Forward-Looking Statements
Forward-Looking Statements
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TREVI THERAPEUTICS, INC. Date: December 12, 2024 By: /s/ Lisa Delfini Name: Lisa Delfini Title: Chief Financial Officer